Adagene's Muzastotug Shows 66.7% Response Rate in Triple Combination Therapy for Hepatocellular Carcinoma at AACR 2026

Key Takeaways

• Muzastotug triple combination therapy achieved 66.7% overall response rate compared to 32.5% for standard treatment in hepatocellular carcinoma patients
• Phase 1b/2 trial results position muzastotug as promising backbone therapy for multiple cancer types including liver cancer
• Data presented at AACR 2026 supports advancement of Adagene’s immunotherapy pipeline with dose-dependent efficacy demonstrated

---

Adagene Presents Breakthrough Data for Muzastotug at AACR 2026

Adagene unveiled compelling clinical data at the American Association for Cancer Research (AACR) 2026 annual meeting, demonstrating muzastotug’s potential as a backbone combination therapy across multiple tumor types. The biotech company presented two posters highlighting significant efficacy improvements in cancer treatment.

Superior Efficacy in Hepatocellular Carcinoma

The most striking results came from a Phase 1b/2 trial evaluating muzastotug in combination with atezolizumab and bevacizumab as first-line therapy for locally advanced or metastatic hepatocellular carcinoma (HCC). The triple combination achieved a 66.7% overall response rate compared to just 32.5% for the atezolizumab plus bevacizumab control arm, as measured by investigators using HCC-specific Modified RECIST v1.1 criteria.

This substantial improvement represents more than double the response rate of the current standard combination therapy, potentially offering new hope for patients with this challenging form of liver cancer.

Dose-Dependent Response Across Cancer Types

Adagene also presented data on a second triple combination featuring muzastotug plus pembrolizumab and fruquintinib, which demonstrated dose-dependent response rates of 25% and 40%. While the complete data set was not fully disclosed in the initial announcement, these results suggest muzastotug’s versatility as a combination partner with different immunotherapy and targeted therapy agents.

Market Implications and Next Steps

The AACR 2026 presentations position Adagene’s muzastotug as a potentially transformative addition to cancer combination therapies. The significant improvement in response rates for hepatocellular carcinoma patients could accelerate the drug’s development timeline and attract partnership opportunities with major pharmaceutical companies.

For the competitive oncology landscape, these results suggest that novel immunotherapy combinations may continue to drive improved patient outcomes, particularly in difficult-to-treat cancers like HCC where treatment options remain limited.

The company is expected to advance these combination strategies into later-stage clinical development based on the encouraging efficacy signals demonstrated across multiple tumor types.

---

Frequently Asked Questions

What does this mean for hepatocellular carcinoma patients?

The 66.7% response rate with muzastotug combination therapy represents a significant improvement over current standard treatment (32.5% response rate), potentially offering better outcomes for patients with advanced liver cancer.

When will muzastotug be available to patients?

Muzastotug is currently in Phase 1b/2 trials. Based on these promising results, Adagene will likely advance to Phase 3 trials, meaning the therapy could potentially be available in 3-5 years if trials continue to show positive results.

How does muzastotug compare to existing hepatocellular carcinoma treatments?

The muzastotug triple combination showed more than double the response rate (66.7%) compared to the current standard combination of atezolizumab plus bevacizumab (32.5%), suggesting significantly improved efficacy.